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Abstract
Osteosarcoma is an often-fatal mesenchyme-derived malignancy in children and young adults. Overexpression of
EMT-transcription factors (EMT-TFs) has been associated with poor clinical outcome. Here, we demonstrated that
the EMT-TF ZEB1 is able to block osteoblastic differentiation in normal bone development as well as in osteosarcoma
cells. Consequently, overexpression of ZEB1 in osteosarcoma characterizes poorly differentiated, highly metastatic
subgroups and its depletion induces differentiation of osteosarcoma cells. Overexpression of ZEB1 in osteosarcoma
is frequently associated with silencing of the imprinted DLK-DIO3 locus, which encodes for microRNAs targeting
ZEB1. Epigenetic reactivation of this locus in osteosarcoma cells reduces ZEB1 expression, induces differentiation,
and sensitizes to standard treatment, thus indicating therapeutic options for ZEB1-driven osteosarcomas.
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great
Britain and Ireland.
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Introduction
Osteosarcoma, the most common primary bone cancer,
particularly affects children and adolescents. Osteosar-
coma is a leading cause of cancer-related death in young
adults. This is mainly due to the early spread of tumor
cells to the lung, the most prevalent site of metastasis
in osteosarcoma patients [1]. Defective osteogenic dif-
ferentiation seems to be an important feature of osteosar-
coma tumorigenesis and may explain its high malignant
potential [2]. However, the causative molecular mecha-
nisms are not fully understood.
Aberrant activation of the epithelial–mesenchymal
transition (EMT) program is widely accepted to be a
major driver of tumor progression in epithelial-derived
malignancies but plays a role in non-epithelial tumors
as well [3,4]. In this regard, overexpression of EMT-
transcription factors (EMT-TFs), including zinc finger
E-box-binding homeobox 1 (ZEB1), was associated
with increased invasion and proliferation of osteosar-
coma cells and poor clinical outcome in osteosarcoma
[5–9]. In many younger osteosarcoma patients, the
DLK1–DIO3 locus exhibits imprinting defects. Result-
ing downregulation of miRNAs encoded therein corre-
lates with shorter overall survival and metastasis [10–
13]. The imprinted DLK1–DIO3 locus represents the
largest miRNA cluster in mammals, including 52 differ-
ent miRNAs [14], of which several have already been
shown to target core EMT-TFs including ZEB1 [8,15–
18]. Thus, silencing of DLK–DIO3 might be involved
in ZEB1 overexpression in osteosarcoma.
In this study, amongst the core EMT-TFs, we selectively
observed a clinically relevant upregulation of ZEB1 in
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osteosarcoma and demonstrated its crucial role in control-
ling differentiation in normal osteoblast development and
maintaining an undifferentiated state of osteosarcoma cells.
Epigenetic reactivation of DLK1-DIO3-encoded micro-
RNAs reduces ZEB1 expression and induces differentia-
tion and chemotherapeutic susceptibility in osteosarcoma




Mouse and human mesenchymal stem cells were cultured
in αMEMwith 10% FBS and 1%penicillin–streptomycin
stock solution. All cell lines were cultivated in DMEM
with 10% FBS. Stably transduced cells were cultured
and selected using 5 μg/ml puromycin (Sigma-Aldrich,
Taufkirchen, Germany; P8833).
Molecular cloning
To analyze the direct regulation of ZEB1 by miRNAs,
the full-length ZEB1 3’-UTR was cloned into the
pMIR-REPORT™ Luciferase plasmid vector (Thermo
Fisher,Waltham,MA,USA;Cat #AM5795). Site-directed
mutagenesis was performed to erase miRNA binding sites
in the ZEB1 3’-UTR. Cloning and mutagenesis were
verified by sequencing.
Virus transduction
Cells were transduced with a multiplicity of infection
(MOI) of 1 overnight. Cells transduced with virus con-
taining GFP were checked for transduction efficiency
by flow cytometry.
For recombination in vitro, mMSCs isolated from
ZEB1flox/flox [19] or R26-Zeb1tg/tg mice [20] were trans-
duced with adeno-Cre virus [21] added to the culture
medium. Recombination efficiency was determined by
genotyping PCR and immunofluorescence analysis.
Transfection of pre-miRNAs and miRNA inhibitors
Transfectionofpre-miRNAsormiRNAinhibitors (designed
as described in ref 22) was performed 24 h after cell seed-
ing with Lipofectamine RNAiMAX (Thermo Fisher;
13778100) according to the manufacturer’s protocol.
RNA and protein isolation was performed after 24 h
(pre-miRNAs) or 72 h (miRNA inhibitors). Details of the
pre-miRNAs and miRNA inhibitors are provided in
supplementary material, Table S1.
Differentiation
Osteoblastic differentiation was induced by osteo-
genic differentiation medium [αMEM, 10% FBS,
1% penicillin–streptomycin stock solution, 200 μM
L-ascorbic acid 2-phosphate (Sigma-Aldrich; A8960),
10 mM β-glycerophosphate (Sigma-Aldrich; G9422)].
To analyze early osteoblastic differentiation, the alkaline
phosphatase activity was determined. Terminal osteo-
blastic differentiation was analyzed via staining of cal-
cium deposits with Alizarin red S (Sigma-Aldrich;
A5533).
Clonogenic capacity
To assess clonogenic capacity, cells were seeded sparsely
in DMEM, 10% FBS. Colonies were fixed with 4% form-
aldehyde after 8 (143B), 14 (MG-63, hMSC_1) or 21 days




assay [thiazolyl blue tetrazolium bromide (Sigma-Aldrich;
M2128)] according to themanufacturer’s protocol.
Drug treatment (in vitro)
A dose–response matrix for cancer cells, treated with 5-
Aza (Sigma-Aldrich, A3656) and doxorubicin (Sigma-
Aldrich; 44583), was generated by adding drugs (day
0) in different dose combinations (5-Aza: 0.256–
10 μM; doxorubicin: 3.125–800 nM). The relative cell
viability for each drug combination was determined after
3 days relative to day 0 and relative to the untreated con-
trol, using an MTT assay (see above). Values were con-
verted into % inhibition and the excess over highest
single agent (HSA) was calculated according to the for-
mula: yHSA = max(y1, y2), where y1 and y2 represent
the effects of corresponding monotherapy.
Western blot analysis
For standard western blotting, the following primary
antibodies were used: ACTB (Sigma-Aldrich; A5441,
1:5000); BGLAP (Santa Cruz Biotechnology, Dallas,
TX, USA; sc-30044, 1:500); HA (Roche, Mannheim,
Germany; 12158167001, 1:500); RUNX2 (Cell Signal-
ing Technology, Danvers, MA, USA; 12556, 1:5000);
and ZEB1 (Sigma; HPA027524, 1:5000). Relative pro-
tein quantification was conducted using ImageLab
(Bio-Rad, Hercules, CA, USA).
RT-qPCR
Total RNA was isolated and reverse transcription per-
formed. cDNA was amplified using Power SYBR Green
PCR master mix (mRNA and lncRNA) (Thermo Fisher;
4367659) or ExiLENT SYBRGreenmaster mix (miRNA)
(Exiqon, Woburn, MA, USA; 203421). Samples were run
in triplicates and normalized to ACTB. Primer sequences
are listed in supplementarymaterial, Table S2.
Methylation-specific PCR
Methylation of MEG3-DMR was analyzed as described
previously [23].
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Lung/liver colonization
All mouse experiments were approved by the Commit-
tee on Ethics of Animal Experiments of the State of
Bavaria (Regierung Unterfranken, Würzburg) and per-
formed according to European Animal Welfare laws
and guidelines.
1 × 105 cells in 200 μl of PBS were injected i.v. in
NSG mice. After 3 weeks, the mice were sacrificed and
GFP-fluorescence images of the lungs/livers were
acquired ex vivo. For in vivo drug treatment, 2 × 105
cells were injected i.v. in NSG mice. Vehicle, doxorubi-
cin (5 mg/kg or 2.5 mg/kg), and 5-Aza (3 mg/kg) were
administered by intraperitoneal injections as depicted.
On day 16, the mice were sacrificed and GFP-
fluorescence images of the lungs were acquired ex vivo.
Subsequently, lungs were fixed in 4% paraformaldehyde
(PFA), embedded in paraffin, sectioned, and stained
with Mayer’s hematoxylin and eosin solution G (H&E).
Skeletal staining
Zeb1del/+ mice were generated by crossing Zeb1flox/flox
mice [19] with Sox2::Cre mice [24]. Embryos at E15.5
were isolated and fixed in 95% ethanol for 24 h. Carti-
lage was stained for 24 h with Alcian blue. Calcification
of bones was detected using Alizarin red S.
Immunohistochemistry
To estimate the differentiation state of osteosarcoma
tumor samples, H&E staining on paraffin-embedded tis-
sue sections was performed. ZEB1, SNAI1, and
TWIST1 immunohistochemistry (anti-ZEB1, Sigma-
Prestige, HPA027524, 1:1000; anti-SNAIL, Cell Signal-
ing Technology, 3879, 1:50; anti-TWIST1, Abcam,
Cambridge, UK; ab50581, 1:100) was performed as pre-
viously described [25]. Samples were used in accor-
dance with ethical guidelines for the use of
retrospective tissue samples provided by the local ethics
committee of the FAU Erlangen-Nürnberg (ethics com-
mittee statements 24.01.2005). Ethical approval for the
TMA cases was given by the ethics committee Basel
(reference 274/12).
Gene expression data analysis
mRNA and miRNA expression and survival data of the
gene expression microarrays: GSE32981 [26],
GSE21257, and GSE69524, were obtained from the
Gene Expression Omnibus database (https://www.ncbi.
nlm.nih.gov/geo/) and analyzed using GEO2R (https://
www.ncbi.nlm.nih.gov/geo/geo2r/) and Microsoft
Excel. mRNA expression data of the E-MEXP-3628
microarray data set were downloaded from the ArrayEx-
press database (https://www.ebi.ac.uk/arrayexpress/)
and analyzed using Microsoft Excel. Kaplan–Meier
curves were based on the log2 values of the corresponding
EMT-TF, which were used to categorize the samples into
low (lower third, n = 18) or high (upper two-thirds,
n = 35) expression.
miRNA prediction
Prediction analysis of ZEB1 3’-UTR-targeting miRNAs
was carried out using online miRNA prediction tools:
TargetScan (http://targetscan.org), miRanda (http://
microrna.org) [27], and miRDB (http://miRDB.org).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software, San Diego, CA, USA). All data are
depicted as mean  SD, unless otherwise specified. The
significance between two groups was determined by an
unpaired two-tailed Student’s t-test (parametric) or an
unpaired two-tailed Mann–Whitney test (nonparametric).
The significance between more than two groups was deter-
mined by a one-way ANOVA with correction for multiple
comparisons usingDunnett’s method (parametric, compar-
ison to one control group) or Tukey’s method (parametric,
comparison between all groups). Proliferation data were
tested for significance using multiple t-tests with correction
for multiple comparisons using the Holm–Sidak method.
Survival data were analyzed with the log-rank (Mantel–
Cox) test. Statistical significance is presented as *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001.
Detailed descriptions of individual methods are pro-
vided in supplementary material, Supplementary mate-
rials and methods.
Results
ZEB1 is downregulated upon osteoblast
differentiation
EMT-TFs are reported to play a role in osteosarcoma. To
assess their differential role in osteosarcoma progres-
sion, we performed a comparative mRNA expression
and survival analysis using publicly available data sets
of primary human osteosarcomas. Remarkably, among
the five core EMT-TFs (SNAI1, SNAI2, ZEB1, ZEB2,
and TWIST1) [4], only ZEB1 was considerably elevated
in osteosarcoma tumor samples relative to non-neoplastic
bone tissues (Figure 1A and supplementary material,
FigureS1A)and tended tobeupregulated in establisheddis-
tant metastasis compared with primary osteosarcomas, in
particular with the non-metastatic tumors (Figure 1B and
supplementary material, Figure S1B). Patients with high
ZEB1 expression in their tumor showed a significantly
shorter overall survival, but no significant differences in
the survival probability were detectable for the other core
EMT-TFs (Figure 1C). Furthermore, in human osteosar-
coma cell lines (hOSCs), ZEB1 protein levels were consis-
tently elevated compared with non-neoplastic bone
marrow-derived human mesenchymal stem cells (hMSCs)
(supplementary material, Figure S1C), which can give rise
to osteosarcomas and are the direct precursors of committed
pre-osteoblasts, the considered cellular origin of osteosar-
coma [28,29]. Interestingly, in vitro differentiated osteo-
blasts, validated by an increased expression of osteoblastic
marker genes and acquired Alizarin red-stained calcium
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deposits, over time also further reduced ZEB1 expression
but slightly upregulated SNAIL and TWIST1 expression
(Figure 1D,E and supplementary material, Figure S1D).
These data indicate that among the core EMT-TFs, espe-
ciallyZEB1 impacts osteosarcomaprogressionandprogno-
sis. Itsdownregulationuponosteoblastdifferentiationpoints
to a potential ZEB1-dependent pathological mechanism
during osteosarcoma progression.
ZEB1 blocks osteoblastic differentiation in
mesenchymal stem cells and osteosarcoma cells
Blocking osteoblastic differentiation is an important aspect
of osteosarcoma progression [2]. The observation of
increased ZEB1 expression in osteosarcoma cells and its
strong downregulation during osteoblastic differentiation
of MSCs prompted us to analyze its role in the osteoblastic
lineage under physiological and pathophysiological condi-
tions. Among many other defects, conventional Zeb1
knockout mice display a variety of skeletal abnormalities
[30] that we could recapitulate using our published Zeb1flox
allele [19]. Strikingly, in E15.5 Zeb1-deficient embryos
(Zeb1del/del), the most severe defect was the shortening of
long bones (Figure 2A and supplementary material,
Figure S2A), which we hypothesized to result from prema-
ture osteoblastic differentiation. To functionally analyze
the role of Zeb1 in this physiological process, we isolated
MSCs from the compact bone of Zeb1flox/flox [19] or
R26-Zeb1tg/tg mice [20], which can be directed to undergo
osteoblastic differentiation. They displayed the typical sur-
facemarker expression ofmouseMSCs (mMSCs) (supple-
mentary material, Figure S2B) [31,32]. Adeno-Cre virus
(a-Cre) transduction led to almost complete knockout
(Zeb1flox/flox) or mild overexpression (R26-Zeb1tg/tg mice)
of Zeb1 (supplementary material, Figure S2C). Induction
of osteoblastic differentiation in non-recombined mMSCs
resulted in increased alkaline phosphatase (ALP) staining,
a marker for early osteoblastic cells, after 7 days. Of note,
Zeb1-depleted cells exhibited spontaneous strong ALP
staining, even without extrinsic induction, highlighting
Figure 1. ZEB1 is elevated in osteosarcoma and correlates with progression and poor survival. (A) Comparative analysis of mRNA expression in
human osteosarcoma tumor samples (n = 14) relative to normal human bone samples (n = 4) (E-MEXP-3628). The heat map illustrates log2
FC values. (B) Comparative analysis of mRNA expression in human osteosarcoma tumor samples without (Met−, n = 4) or with (Met+, n = 7)
detectable metastases and distant metastasis samples (n = 11) (GSE32981). The heat map illustrates log2 FC values. (C) Kaplan–Meier curves
showing the overall survival probability dependent on low (lower third, n = 18) or high (upper two-thirds, n = 35) expression of the corre-
sponding EMT-TF (GSE21257); log-rank (Mantel–Cox) test. (D) Representative western blot and chemiluminescence-based protein quantifi-
cation of ZEB1, RUNX2, and osteocalcin (BGLAP) in hMSC_1 cells cultured with or without osteogenic differentiation medium (ODM) for
21 days. ACTB was used as a loading control. n = 3, mean  SD; Student’s t-test (two-tailed). (E) Representative phase-contrast images
of hMSC_1 cells used in D. Alizarin red staining at day 21. Scale bars: 200 μm.
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Figure 2. ZEB1 regulates osteoblastic differentiation inmesenchymal stemcells andosteosarcomacells. (A) Representative images ofAlizarin red/Al-
cianbluestainingoftheskeletonsfromE15.5Zeb1+/+ (n = 5),Zeb1del/+ (n = 3),andZeb1del/del (n= 4)embryos.Arrowheadsmarkskeletaldefects. (B,C)
Representative alkaline phosphatase (ALP) staining at day 7andAlizarin red staining at day 21of untreated anda-Cre transduced Zeb1flox/floxmMSCs
(B) or R26-Zeb1tg/tg mMSCs (C) cultured with or without osteogenic differentiation medium (ODM). n = 3. (D) Representative images of H&E and
immunohistochemical ZEB1, TWIST1, and SNAI1 staining of osteosarcoma tumors. For cases 1 and2, a poorly differentiated andawell-differentiated
area are shown. Asterisks mark osteoid deposition. Scale bar: 50 μm. (E) Example images of immunohistochemical ZEB1 staining of a well- and a
poorly-differentiated tumor in the osteosarcoma tissue microarray (TMA). Asterisks mark osteoid deposition. Scale bar: 50 μm. H-scores of poorly
(n = 11)andwell (n = 103)-differentiated tumors.H-score is the sumof four staining intensities (0 = negative, 1 = low,2 = medium,3 = high)mul-
tipliedby thecorrespondingpercentageofpositive stainedcells, resulting ina scaleof0–300.Boxandwhiskers plot:whiskers = min/max;box = 25th
to 75th percentiles;middle line = median; plus = mean.Mann–Whitney test (two-tailed). (F) Representative alkaline phosphatase (ALP) staining and
Alizarin red staining at day 21 of HOS cells stably transducedwith shCtrl, shZEB1_A or shZEB1_B vector, cultured with or without osteogenic differ-
entiation medium (ODM). n = 3. (G) Representative western blot for ZEB1, RUNX2, and osteocalcin (BGLAP) for cells used in F after 21 days. n = 2.
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ZEB1 as a gatekeeper of osteoblastic differentiation. Fur-
thermore, Zeb1 knockout cells also revealed increased ter-
minal differentiation compared with non-recombined cells,
indicated by increased alizarin red staining (Figure 2B). On
the other hand, Zeb1 overexpression effectively diminished
osteogenic differentiation (Figure 2C). Consistent with this,
we observed similar effects in humanMSCs. Stable knock-
down of ZEB1 by two independent short hairpin RNAs
(shRNAs) increased the proportion of ALP-positive early
osteoblastic cells already without induction of osteoblastic
differentiation. Of note, terminal differentiation was only
increased with the more potent knockdown (shZEB1_B),
indicating a dose-dependent effect (supplementary mate-
rial, Figure S2D,E).
To translate these findings to the cancer context and
correlate the expression of ZEB1 with the degree of dif-
ferentiation in human primary osteosarcomas, we ana-
lyzed tumors which exhibited substantial intratumoral
heterogeneity with poorly and well-differentiated areas
in close proximity as determined by the relative number
of cells compared with deposited extracellular matrix
[33]. Poorly differentiated areas displayed strongly ele-
vated ZEB1 protein levels compared with well-
differentiated areas (Figure 2D). Additionally, staining
of a tissue microarray (TMA) of 114 osteosarcomas also
revealed increased ZEB1 expression in poorly differenti-
ated tumors (Figure 2E). We could further support these
results in vitro using an shRNA-mediated knockdown of
ZEB1 in human HOS osteosarcoma cells (Figure 2F).
ZEB1-expressing control cells (shCtrl) were non-
responsive to the osteoblastic stimulus and did not show
any signs of differentiation. However, knockdown of
ZEB1 induced an early osteoblastic ALP-expressing
phenotype in HOS cells already without extrinsic induc-
tion of osteoblastic differentiation, akin to the
ZEB1-depleted MSCs (Figure 2B and supplementary
material, Figure S2E). As seen before in the MSCs, the
more potent knockdown (shZEB1_B) induced a termi-
nal differentiation even in this aggressive osteosarcoma
cell line, shown by strong Alizarin red staining
(Figure 2F). Interestingly, ZEB1 could not be downregu-
lated in HOS shCtrl cells under differentiation condi-
tions, unlike that seen before in normal MSCs.
However, shRNA-mediated depletion of ZEB1 strongly
increased the expression of RUNX2, the master regula-
tor of osteoblastic differentiation, and under differentia-
tion conditions also led to an increase of the terminal




and consequently prevents differentiation in osteosarcoma
cells when aberrantly highly expressed, eventually locking
the tumor cells in an aggressive, undifferentiated state.
ZEB1 stimulates metastatic colonization
Expression of ZEB1 in osteosarcoma cells has already
been correlated with increased proliferation as well as
with migration and invasion [8,34]. We established
stable shRNA-mediated knockdown of ZEB1 in differ-
ent osteosarcoma cell lines, as well as moderate overex-
pression of ZEB1 in the relatively low-expressing Saos-2
cells (supplementary material, Figure S3A,B), and con-
firmed ZEB1-dependent invasion capacity in different
osteosarcoma cell lines (supplementary material,
Figure S3C). Of note, in our hands, cell proliferation
was not affected by ZEB1 knockdown or overexpression
(supplementary material, Figure S3D,E), which is con-
tradictory to published data [8,9]. However, the most rel-
evant part of clinical progression is metastasis to the
lung. Here, the critical step is metastatic colonization,
the seeding of colonies in the novel environment at the
distant site. This colonization capacity is highly depen-
dent on stemness, survival, and plasticity traits, which
are all known to be exerted by ZEB1 [35].
Using our stable cell lines, ZEB1 knockdown strongly
reduced, whereas overexpression enhanced in vitro clo-
nogenic capacity (Figure 3A,B). The same effect was
seen in non-neoplastic human MSCs, in which ZEB1
depletion completely abolished the ability to form colo-
nies without affecting cell proliferation (supplementary
material, Figure S3F,G). These data demonstrate a gen-
eral function of ZEB1 in the clonal outgrowth of mesen-
chymal cells.
To further determine whether ZEB1 facilitates coloniza-
tion and subsequent metastatic outgrowth in vivo, we used
the highly metastatic 143B osteosarcoma cell line in an
experimental metastasis assay. Tumor cells were injected
into the tail vein of immunodeficient mice and the forma-
tion of macrometastases in the lung and liver was assessed
after 3 weeks. ZEB1 knockdown significantly reduced the
number of metastatic colonies in the lung (Figure 3C and
supplementary material, Figure S3H) and the liver
(Figure 3D and supplementary material, Figure S3I).
Taken together, these data provide evidence that aber-
rant ZEB1 expression increases the colonization capac-
ity and promotes metastasis formation of osteosarcoma
cells.
Loss of imprinting at the DLK1–DIO3 locus enables
indirect epigenetic targeting of ZEB1-driven
osteosarcomas
Our data show that ZEB1 expression in osteosarcoma
blocks differentiation and increases the metastatic colo-
nization capacity. Since metastasis is the major cause
of death for osteosarcoma patients, ZEB1 would be a
candidate therapeutic target. But because transcription
factors are hard to target, we focused on its upstream reg-
ulation. On the one hand, previous studies have sug-
gested that the miR200 family, which is reciprocally
linked to ZEB1 expression by a double-negative
ZEB1/miR200 feedback loop in epithelial cells [36], is
involved in the progression of osteosarcoma [37,38].
However, our analysis revealed that they were not differ-
entially and were very weakly expressed in hMSCs and
hOSCs (Figure 4A) and that their inhibition in hMSCs
had no effect on ZEB1 expression (supplementary mate-
rial, Figure S4A,B). On the other hand, there is the
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imprinted DLK1-DIO3 locus, which is dysregulated in
90% of osteosarcomas [13] and encodes a large cluster
of microRNAs (Figure 4B). Their downregulation in oste-
osarcoma correlates with shorter overall survival and
metastasis [10–12]. By analyzing the expression of the
DLK1-DIO3 miRNAs in the NCI sarcoma cell line panel
[40], we could confirm substantially decreased expression
levels of these miRNAs in osteosarcoma cell lines com-
pared with normal human non-neoplastic connective tissue
cells or other sarcoma subtypes (Figure 4C). 73% of the
DLK1-DIO3 encoded microRNAs are supposed to target
ZEB1 (Figure 4D). RT-qPCR confirmed the downregula-
tion of the top six ZEB1-targeting of these microRNAs
(calculated by three different microRNA target prediction
tools) in osteosarcoma cell lines compared with hMSCs
(Figure 4E).
Overexpression of silenced individual or particularly
the combination of the top six DLK1-DIO3 encoded
microRNAs reduced ZEB1 expression to a similar
extent to our positive control, MIR200c (Figure 4F).
Moreover, combined downregulation of only three
endogenous microRNAs of the cluster, namely
MIR409-3p, MIR431-3p, and MIR655-3p, in hMSCs
by anti-MIRs led to increased ZEB1 expression
(Figure 4G,H). Interestingly, these three miRNAs have
already been linked to ZEB1 suppression [8,16,18].
We could confirm that they directly targeted ZEB1 3’-
UTR in luciferase reporter assays, where transfection
of pre-MIR431-5p, pre-MIR409-3p, and pre-MIR655-3p
significantly reduced the luciferase activity, while muta-
tion of their respective seed sequences resulted in a com-
plete rescue (supplementary material, Figure S4C–F).
Next,wewanted to test if a pharmacologic reactivation
of silenced endogenous microRNAs encoded in
DLK1-DIO3, which should lead to ZEB1 repression,
was feasible. Apart from the miRNAs, the imprinted
locus also contains three long non-coding RNAs
(lncRNAs):MEG3,MEG8, andMEG9. TheDLK1-DIO3
locus is tightly regulated by two differently methylated
imprinting control regions (IG-DMR, MEG3-DMR).
Hypermethylation of theMEG3-DMR is associated with
reduced expression of the maternally expressed non-
coding RNAs [41,42]. Using a methylation-specific
PCR [23] (Figure 5A), we observed that all hMSCs
showed the predicted equal amount of unmethylated
and methylated PCR product, whereas we detected a
reduction in the unmethylated PCR product in three out
of five hOSCs (Figure 5B), fitting with the silencing of
the microRNAs. Treatment of hOSCs with the demethy-
lating agent 5-aza-2’-deoxycytidine (5-Aza) resulted
Figure 3. ZEB1 facilitates tumorigenic traits of osteosarcoma cells in vitro and in vivo. (A) Representative images and quantification of colony
formation assays with 143B (8 days), MG-63 (14 days), and Saos-2 (21 days) cells stably transduced with shCtrl, shZEB1_A or shZEB1_B vec-
tor. n = 3 (143B), n = 5 (MG-63, Saos-2), mean  SD; one-way ANOVA with correction for multiple comparisons using the Dunnett method.
(B) Representative images and quantification of colony formation assays with Saos-2 cells (21 days) stably transduced with empty vector
(EV) or HA-tagged ZEB1 (ZEB1 OE). n = 4, mean  SD; Student’s t-test (two-tailed). (C, D) Ex vivo GFP-fluorescence imaging and quantifi-
cation of macrometastases per lung (C) and liver (D) 3 weeks after injection of 1 × 105 143B cells into the lateral tail vein of immunodeficient
NSG mice: shCtrl (n = 6) or shZEB1_B (n = 6). Representative overview pictures of the liver are assembled out of four individual images.
Mean  SD; Student’s t-test (two-tailed).
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in the re-expression of MEG3, MEG8, and MEG9, as
well as MIR409-3p and MIR431-5p, representing
both miRNA sub-clusters in the DLK1-DIO3 locus
(Figure 5C). Reciprocally, 5-Aza treatment downregu-
latedZEB1protein levels in 143B,HOS, andSaos-2 cells
(Figure 5D).
Figure 4. LossofmiRNAsencodedbythe imprintedDLK1-DIO3 locusdrivesZEB1overexpression inosteosarcoma. (A)RT-qPCRanalysisof themiRNA-
200 familymembers on chromosome (Chr) 1 and Chr 12. The heatmap illustrates the expression values of hMSCs and hOSCs relative to epithelial ‘E’
MCF7andmesenchymal-like ‘M’MDA-MB-231breast carcinomacell lines.n = 3,mean (SD is not depicted). Statistical comparisonof hMSCs versus
hOSCs: Mann–Whitney test (two-tailed). (B) Schematic representation of the DLK1-DIO3 locus on human chromosome 14q32. The lncRNAs (MEG3,
MEG8, andMEG9),miRNAs,andsnoRNAs(notdepicted)areexpressedfromthematernally inheritedchromosomeandtheprotein-codinggenes (DLK1,
RTL1, andDIO3) from the paternally inherited chromosome. Open boxes represent repressed genes. The imprinting status is determined by two differ-
entiallymethylated regions (DMRs), the intergenicDMR (IG-DMR)and theMEG3-DMR (green = unmethylated; red = methylated). AllmiRNAsof the
locus are depicted and classified into two sub-clusters. Adapted from [39]. (C) Comparative expression analysis of miRNAs located in the DLK1-DIO3
locus. The GSE69524 data set was used, comparing human sarcoma cell lines relative to human non-neoplastic connective tissue cell lines. The heat
map illustrates log2 values.N = human non-neoplastic connective tissue cells (n = 5); OS = human osteosarcoma cell lines (n = 10); EWS = human
Ewing’s sarcoma cell lines (n = 23); CS = human chondrosarcoma cell lines (n = 3); STS = human soft tissue sarcoma cell lines (n = 36); HK = ‘hou-
sekeeping’genes (MIR16-5pandMIR191-5p). (D)NumberofDLK1-DIO3miRNAs that are predicted to target theZEB13’-UTRbyat least oneof three
onlinemiRNAtargetpredictionprograms(TargetScan,miRanda,andmiRDB). (E)RT-qPCRanalysisofmiRNAsinhMSCsandhOSCs.n = 3,mean  SD;
Mann–Whitney test (two-tailed). (F) Representativewesternblots of143BandMG-63cells transfectedwith the indicatedpre-miRNAs for24 h.ACTB
wasusedasa loadingcontrol. pos.=positivecontrol;n = 3. (G)RT-qPCRanalysisofmiRNAs inhMSC_1cells transfectedwithanti-MIRcontroloranti-
MIR431-5p/anti-MIR409-3p/anti-MIR655-3pmiRNA inhibitors for 72 h. n = 3,mean  SD; Student’s t-test (two-tailed). (H) Representativewest-
ern blot for ZEB1 in hMSC_1 cells used in G. n = 3.
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Figure 5. Loss of imprinting at the DLK1-DIO3 locus enables indirect epigenetic targeting of ZEB1-driven osteosarcomas. (A) Schematic rep-
resentation of primer binding sites for the methylation-specific PCR of the MEG3-DMR. Adapted from [23]. (B) Methylation-specific PCR
screen of bisulfite-treated genomic DNA of hMSCs and hOSCs with primers shown in A. M = PCR product of methylated-DNA specific primers
(160 bp); U = PCR product of unmethylated-DNA specific primers (120 bp). (C) RT-qPCR analysis of miRNAs, lncRNAs, and ZEB1 in hOSCs
treated with 5-aza-2’-deoxycytidine (5-Aza) for 72 h. Dimethyl sulfoxide (DMSO) was used as a vehicle treatment control. n = 3, mean  SD.
(D) Western blot analysis for ZEB1 of cells used in C. ACTB was used as a loading control. n = 3. (E) Representative alkaline phosphatase (ALP)
staining at day 14 and Alizarin red staining at day 21 of HOS cells cultured with or without osteogenic differentiation medium (ODM) and
treated with 5-Aza or DMSO for the indicated time. n = 3. (F) Top: dose–response matrix of 5-Aza and doxorubicin in HOS, 143B, and
Saos-2 cells. Bottom: excess over highest single agent (HSA) matrix. n = 2. (G) Ex vivo GFP-fluorescence imaging and quantification of
macrometastases per lung 16 days after injection of 2 × 105 143B cells into the tail vein of NSG mice: vehicle (n = 7), Doxo (n = 6), 5-
Aza (n = 8) or Doxo + 5-Aza (n = 7) was administered i.p. as depicted. Mean  SD. (H) Quantification of metastasis-affected lung area from
H&E staining of two representative sections (distance 200 μm) per lung using ImageJ. Mean  SD; unpaired Student’s t-test.
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Poorly differentiated osteosarcomas show a much
higher risk of developing metastases and local recurrence
than well-differentiated tumors [33,43]. This is further
underlinedby in vitro studies showing that osteoblasticdif-
ferentiation in osteosarcoma cells reduces their malignant
potential [44,45]. Thus, we tested if reactivation of hyper-
methylated DLK1-DIO3 miRNA genes would induce
osteoblastic differentiation similar to an artificial downre-
gulation of ZEB1. Indeed, 5-Aza-treatedHOS cells exhib-
ited a higher proportion ofALP-positive early osteoblastic
cells and strong induction of terminal differentiation under
differentiation conditions, demonstrated by distinct Aliza-
rin red S staining (Figure 5E), similar to a ZEB1 knock-
down in these cells (compare Figure 2F). Since in
carcinoma, expression of EMT-TFs is strongly associated
with a drug resistance phenotype [3,35], we determined
whether 5-Aza treatment of osteosarcoma cells also
increases sensitivity to standard chemotherapeutic drugs,
such as doxorubicin. Using a dose–response matrix of
45 different combinations of 5-Aza and doxorubicin dose
levels, we detected an excess over the highest single agent
response (HSA) at low doxorubicin concentrations in dif-
ferent osteosarcoma cell lines (Figure 5F). To confirm
theseresults invivo,we injected143Bcells i.v. andallowed
metastasis formation for 1 week before starting treatment
with vehicle, doxorubicin, 5-Aza or a combination. As
expected, all groups developed similar numbers of lung
metastases, but 9 days of treatment led to a significant
reduction in tumor size.Notably, the combinationofdoxo-
rubicin and 5-Aza exerted the strongest inhibitory effect
also in vivo (Figure 5G,H and supplementary material,
Figure S5A,B). Therefore, a combination of 5-Aza with
the standard chemotherapeutic treatment regimen might
be a promising option for osteosarcoma therapy by induc-
ing differentiation and increasing sensitivity to standard
chemotherapy.
Discussion
The functional relevance of EMT-TFs in the progression
of a variety of carcinomas is well known [35,46,47].
However, their function in sarcomas is only just emerg-
ing. We show here that of all core EMT-TFs, only ZEB1
was strongly elevated in primary osteosarcomas and its
high expression was associated with poor clinical out-
come. Furthermore, we demonstrated a crucial role of
ZEB1 for maintaining an undifferentiated state in MSCs
and osteosarcoma cells. ZEB1 is critical for the coloniza-
tion capacity of osteosarcoma cells, which likely
explains its association with poor prognosis andmetasta-
sis in patients [34]. We could confirm a direct link
between aberrantly high ZEB1 expression and the
well-described dysregulation of imprinted DLK1-DIO3
miRNA genes in osteosarcoma. Their reactivation by
epigenetic drugs led to downregulation of ZEB1, facili-
tated differentiation, and increased sensitivity to stan-
dard chemotherapy in vitro and in vivo, indicating a
promising therapeutic option for fatal osteosarcomas.
Why does ZEB1 play such a prominent role in osteo-
sarcoma? Our data demonstrate that regulated expres-
sion of ZEB1 is important for physiological bone
development and homeostasis.We detected several bone
defects in Zeb1-deficient mice, in particular a shortening
of long bones. In part, these bone defects can be
explained by alterations in the proliferation and pattern-
ing of chondrocytes in the growth plate of Zeb1-depleted
mice [48]. However, our in vitro data using isolated
MSCs provide evidence that ZEB1 also plays an impor-
tant role in controlling the differentiation of osteoblasts.
We showed that ZEB1 is markedly downregulated dur-
ing osteoblastic differentiation and its depletion results
in a premature differentiation of MSCs, which might
also explain the observed shortening of long bones.
Strikingly, different EMT-TFs seem to play different
roles in osteoblastic differentiation. Similar to Zeb1,
Twist1 overexpression inhibits osteoblastic differentia-
tion [49]; however, we found Twist1 to be only weakly
expressed in hMSCs and not considerably regulated
upon osteogenic differentiation. Further, it seems not to
be relevant in osteosarcoma, as we did not detect any
overexpression. In contrast to ZEB1, Weiss and co-
workers showed that a double knockout of Snai1 and
Snai2 in MSCs results in suppression of terminal osteo-
blastic differentiation [50,51]. These data underscore the
non-redundant and partially opposing functions of
EMT-TFs [35,47] and indicate why ZEB1 particularly
plays a crucial role in osteosarcoma. Indeed, we found
that ZEB1 is significantly more highly expressed in
poorly differentiated human osteosarcomas compared
with more differentiated subtypes.
Many osteosarcoma cell lines have lost the ability to
undergo osteoblastic differentiation [52]. We showed that
ZEB1 depletion in differentiation-incompetent HOS cells
renders them susceptible to a differentiation stimulus until
terminal differentiation. Of note, our data provide evidence
that a ZEB1-mediated repression of RUNX2 causes the
block of osteoblastic differentiation in these cells. Besides
the inhibition of osteoblastic differentiation, we also dem-
onstrated that ZEB1 promotes clonal growth and conse-
quently metastatic colonization of osteosarcoma cells.
This is of utmost importance, as early spread of tumor cells
is the major obstacle in the treatment of osteosarcoma
patients. It is considered that undetectable micrometastases
are present in the lungs of about 80% of patients at the time
of diagnosis [53], which drops the survival rate from
approximately 70% in patients with localized disease down
to 20% in patients with metastatic or relapsed tumors [54].
In summary, our findings support the view that osteosar-
coma formation and progression are driven by impaired
osteoblastic differentiation and indicate that elevated
expression of ZEB1 is an important molecular cause by
blocking osteoblastic differentiation and keeping tumor
cells in an undifferentiated aggressive state.
The imprinted DLK1-DIO3 locus represents the larg-
est miRNA cluster in mammals, including 52 different
miRNAs [14] with mostly unknown physiological role.
The deregulation of some DLK1-DIO3 encoded miR-
NAs is associated with the progression of several tumor
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entities such as squamous cell carcinoma, gastrointestinal
cancer, and glioma [55]. Strikingly, in almost 90% of
osteosarcoma patients younger than 30 years, the
DLK1-DIO3 locus exhibits imprinting defects and down-
regulationof the encodedmiRNAscorrelateswith shorter
overall survival and metastasis [10–13]. Our in silico
analysis predicted ZEB1 as a target of the majority of the
52DLK1-DIO3miRNAs. The redundancy of these miR-
NAs in limiting the expression of ZEB1 indicates an
important role of the DLK1-DIO3 cluster in regulating and
fine tuning ZEB1 expression. Besides ZEB1, DLK1-DIO3
miRNAs were also shown to repress other osteosarcoma
drivergenes, suchasYBX1andMYC, altogetherdemonstrat-
ing the important tumor-suppressive role of the locus in this
tumor entity [12,56].
Our data indicate that hypermethylation of the imprinted
DLK1-DIO3 locus is likely the major reason for the lost
miRNA expression in osteosarcoma. Instantly, the aberrant
hypermethylation of the DLK1-DIO3 locus paves the way
for a potential therapeutic intervention. Due to the lack of
specific inhibitors of ZEB1, the epigenetic reactivation of
the DLK1-DIO3 miRNAs by the FDA-approved drug
5-Aza may represent an applicable way to control the aber-
rant expression of ZEB1 in osteosarcoma but also of other
associated driver factors, such as MYC. We demonstrated
that 5-Aza treatment induces terminal differentiation of
osteosarcoma cells, at least in part due to the DLK1-DIO3
miRNA-mediated downregulation of ZEB1. Efficient
treatment of osteosarcoma by demethylation with 5-Aza
was recently demonstrated in a mouse xenograft model
[57]. However, based on the pleiotropic effects of epige-
netic drugs, it is likely that the regulation of other factors
is also involved in this process. Clinically relevant, our data
further indicate a synergistic effect in inhibiting metastatic
growth using a combination of 5-Aza and the standard che-
motherapeutic doxorubicin.
In summary, we have characterized here the important
role of ZEB1 in controlling both osteoblastic differentia-
tion and the formation and progression of osteosarcoma.
Furthermore, our findings highlight a therapeutic option
for this fatal disease.
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